Table 1 Characteristics of participants with sample collected (and tested) for serologic antibody test on same day as sample that resulted in RT-PCR positive for SARS-CoV-2 (n = 492)
Characteristic | Total (n = 492) | Negative antibody test (n = 262) | Positive antibody test (n = 230) | p–valuea |
|---|---|---|---|---|
Age, mean (SD) | 48.4 (20.1) | 47.0 (21.1) | 49.9 (18.9) | 0.10 |
Female, n (%)b | 257 (52.2) | 126 (48.1) | 131 (57.0) | 0.07 |
Any contact history, n (%) | 249 (50.6) | 127 (48.5) | 122 (53.0) | 0.36 |
Reported having any symptoms, n (%) | 372 (75.6) | 206 (78.6) | 166 (72.2) | 0.12 |
Cough | 244 (49.6) | 132 (50.4) | 112 (48.7) | 0.78 |
Sore throat | 180 (36.6) | 105 (40.1) | 75 (32.6) | 0.10 |
Fever | 171 (34.8) | 106 (40.5) | 65 (28.3) | 0.01 |
Nasal congestion | 127 (25.8) | 77 (29.4) | 50 (21.7) | 0.07 |
Difficulty breathing | 61 (12.4) | 26 (9.9) | 35 (15.2) | 0.10 |
Malaise | 179 (36.4) | 103 (39.3) | 76 (33.0) | 0.18 |
Diarrhea | 65 (13.2) | 34 (13.0) | 31 (13.5) | 0.98 |
Vomiting | 52 (10.6) | 23 (8.8) | 29 (12.6) | 0.22 |
Headache | 162 (32.9) | 90 (34.4) | 72 (31.3) | 0.53 |
Loss of taste or smell | 27 (5.5) | 12 (4.6) | 15 (6.5) | 0.46 |
Median number of days since onset of symptoms, among those reporting symptoms (range) (N = 372) | 7 (1–31) | 5 (1–31) | 9 (2–31) | < 0.01 |
Cough (n = 244) | 7 (1–24) | 5 (1–24) | 8 (2–24) | < 0.01 |
Sore throat (n = 180) | 6 (1–28) | 5 (1–18) | 9 (2–28) | < 0.01 |
Fever (n = 171) | 4 (1–22) | 3.5 (1–18) | 7 (1–22) | < 0.01 |
Nasal congestion (n = 127) | 6 (1–31) | 4.0 (1–31) | 9 (1–31) | < 0.01 |
Difficulty breathing (n = 61) | 7 (1–29) | 4 (1–15) | 8 (2–29) | < 0.01 |
Malaise (n = 179) | 6 (1–24) | 5 (1–19) | 8 (1–24) | < 0.01 |
Diarrhea (n = 65) | 6 (1–24) | 3 (1–24) | 7 (1–24) | < 0.01 |
Vomiting (n = 52) | 4 (0–24) | 3 (1–9) | 7 (2–21) | < 0.01 |
Headache (n = 162) | 5 (1–21) | 5 (1–19) | 7 (1–21) | < 0.01 |
Loss of taste or smell (n = 27) | 5 (2–16) | 3.5 (3–10) | 7 (2–16) | 0.03 |